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Recurrent urinary tract infections (RUTI) are prevalent and pose signiﬁcant clinical challenges. Although
the term RUTI has long been vaguely deﬁned, a consensus deﬁnition has emerged in recent years. The
exact etiology behind RUTI remains under debate, with valid arguments for both ascending reinfections
as well as persistent infection inside the bladder. These persistent infections exist in the form of
quiescent intracellular reservoirs in the mouse model and may represent a novel concept to explain UTI
recurrence in humans. Manageable risk factors such as behavioral patterns alongside nonmanageable
risk factors including genetic susceptibility are growing ﬁelds of investigation. Acute UTI have been
studied through two model bacterial strains: Escherichia coli UTI89 and CFT073. However, the clinical
relevance to RUTI of these two strains has not been ﬁrmly established. Current treatment strategies for
RUTI are limited and remain dominated by antibiotic usage despite variable efﬁcacy. The majority of
studies in humans have focused on younger groups of women with little information available about the
postmenopausal population despite a heightened risk of RUTI in this age group.
Copyright  2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license.1. Introduction
Urinary tract infections (UTI) are the most common adult bac-
terial infection in the world.1 In 2000, an estimated $2.5 billionwas
spent on UTI treatment excluding outpatient prescriptions.2
Considering that the majority of women presenting with UTI
have a history of more than two previous infections, recurrence
represents a substantial social cost.3 Recurrence also poses signif-
icant clinical challenges and has a major impact on quality of life.
Unfortunately, few long-term or follow-up studies of recurrent UTI
(RUTI) have been published to guide in evaluation and treatment.
Current evidence indicates that the rate of recurrence following an
initial UTI is high. A 1990 study at the University of Michigan
involving female students aged 17e39 years showed that after a
single UTI event, 27% of women will experience a second recur-
rence in the following 6 months with a further 3% experiencing a
third UTI within the same time period.4 An older study from
Denmark showed that for women aged 16e65 years, rate of
recurrence is highest during the ﬁrst 2 months post-treatment and
between 25% and 35% of women will have recurrence within 3e6l Center, 5323 Harry Hines
n.edu (P. Zimmern).
ciation. Published by Elsevier Taiwmonths.5 Studies of UTI recurrence that include older women are
rarer still. The results of a single study on recurrence in Finnish
women indicated that 44% of women aged 17e82 years will
experience recurrence within 12 months.6 Rates of infection have
been found to be lowest in the winter months.7 Interestingly, the
majority of women experiencing recurrence do so despite culture
directed antibiotic treatment, having no anatomical abnormalities
in the lower and upper urinary tracts, and being otherwise healthy
individuals.8
In this review, we have considered only women suffering from
RUTI who are otherwise normal with no obvious causal factor.
Subpopulations excluded include pregnant women, infants, di-
abetics, patients with neurogenic bladder-like multiple sclerosis
or AIDS, and individuals with abnormal genitourinary anatomy.
Current guidelines for the diagnosis and management of RUTI in
women along with indications for specialist referrals are beyond
the scope of this review, but can be found elsewhere.9 Following
a systematic review of RUTI literature, we present a current up-
date on how UTIs are deﬁned, animal models and strains to study
RUTI, risk factors for recurrence among different age groups,
relevant clinical studies, and therapeutic options.
2. Deﬁnition
Until 2000, there was no generally accepted and broadly used
deﬁnition for RUTI in women. Since then, the majority ofan LLC. Open access under CC BY-NC-ND license.
Fig. 1. Uropathogenic Escherichia coli model for acute cystitis, chronic cystitis, and quiescent intracellular reservoir formation: intracellular bacterial community (IBC) formation
starts when bacteria attach onto the apical transitional epithelium of the bladder via type 1 pili. These bacteria are then enveloped and invade the epithelium d replicating and
forming IBCs. As a host response to infection, the urothelium typically exfoliates, resulting in IBC liberation and IBC recreation in a clonal fashion. IBCs may also progress to quiescent
intracellular reservoirs, which are not metabolically active and do not produce a measurable inﬂammatory response.
Note. From “Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection,” by T.J. Hannan, M.
Totsika, K.J. Mansﬁeld, K.H. Moore, M.A. Schembri, and S.J. Hultgren, 2012, FEMS Microbiol Rev, 3, p. 616e48. Copyright 2012, Nature Publishing Group. Reprinted with
permission.
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sodes of urinary tract infections during the previous 12
months”.8,10e18 Additionally, six publications included a non-
mutually exclusive alternative of “at least two episodes of UTI
during the previous 6 months”.10,11,13,14,16,18 Proof of a positive urine
culture was also frequently incorporated in the deﬁnition8,11,15 with
a speciﬁc concentration of > 103 colony forming units/mL
mentioned in one instance.15 Therefore, to deﬁne RUTI as “three
episodes of urine culture positive UTI in the previous 12 months or
two episodes within the 6 months” represents an acceptable
compromise in contemporary studies.
3. Etiology
There is evidence to support that RUTIs may be caused by one
of two mechanisms: repeated ascending infections or chronic/
persistent infection in the bladder. Repeated ascending in-
fections are thought to occur by the endogenous rectal ﬂora via a
fecaleperinealeurethral route. Bacteria migrate from the
gastrointestinal tract into the periurethral area, ultimately
ascending the urethra into the bladder. The ﬁnding that causa-
tive Escherichia coli strains are often detectable in a women’s
endogenous rectal ﬂora during active UTIs as well as the fact that
sexual intercourse is known to be a deﬁnitive risk factor for RUTI
support this hypothesis.19,20 In addition, women who suffer from
RUTI have been found to have a higher frequency of infection
with endogenous rectal ﬂora, speciﬁcally E. coli and Enterococcus
faecalis.21However, several observations have countered this acceptable
theory of ascending infections. First, following initial treatment
with commonly used antibiotics, 77% of UTIs observed were due to
a relapse with an E. coli strain identical to the primary infecting
strain.8 Second, antibiotics applied to the perineal area have been
shown to be ineffective in reducing the risk of RUTI.22 Finally, it has
been noted that following antibiotic treatment, E. coli in the fecal
ﬂora are reduced in number.23 That is to say, the fecal ﬂora repre-
sents an unstable reservoir for recurrence. This evidence argues for
an alternative source of infection.
One such plausible alternative is the survival of bacteria in the
urinary bladder through the progression of transient intracellular
bacterial communities (IBC) into persistent quiescent intracellular
reservoirs (QIR). IBC formation and its relationship to bacterial
colonization was ﬁrst studied in the late 1970s with the support of
data gathered from aquatic ecosystems. This theory was then
applied to industrial water systems where bacterial bioﬁlms
represent a major concern.24 To date, the majority of studies on
RUTI-related IBC creation and subsequent QIR formation have been
performed in murine models with E. coli strains UTI89 and
CFT073.25e28 Through the work of Hultgren et al,29e33 the murine
IBC/QIR pathogenic cycle has been gradually elucidated and is now
largely understood.
IBCs are initially created when bacteria ascend the urethra and
attach onto the bladder urothelium. In E. coli, luminal attachment
is mediated via type 1 pili and results in urothelial envelop-
ment.30 Initial IBC formation is rapid and can be seen as early as 3
hours postinoculation.31 By 12 hours postinfection, over half of all
Fig. 2. Ascending reinfection. Uropathogens originate from the rectal ﬂora and colonize the periurethral area leading to ascension through the urethra into the bladder.
Note. From “Pathogenic Escherichia coli” by J.B. Kaper, J.P. Nataro, and H.L. Mobley, 2004. Nat Rev Microbiol, 2, p. 123e40. Copyright 2004. Nature Publishing Group. Reprinted with
permission.
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cate while protected from innate immune defenses such as
neutrophil phagocytosis.33 However, the majority of the bacteria
are expelled from the bladder through TLR-4 dependent uro-
thelial hyperplasia. The bacteria that escape this expulsion
remain to create clonal recurrent IBCs as this process repeats
itself.35
Acute IBC formation can result in a simple resolution, but the
infection may also persist in the form of either chronic cystitis or
QIRs. Chronic cystitis can be deﬁned as persistent bacteriuria,
which differs from recurrence. Recurrence implies that there is a
period of time without bacteriuria or signs of infection. Through
ﬂuorescent tagging studies, it has been shown that during the
initial acute infection, higher numbers of IBCs are more predictive
of chronic cystitis than QIR formation.35 Although IBC expulsion
and reformation may undergo many cycles and be called chronic,
this process is limited by the fact that in response to infection, the
bladder urothelium becomes hyperplastic. The underlying smaller
maturing urothelial cells left after exfoliation cannot support large
IBCs.32 As a result, each round of IBC formation is associated with
slower bacterial replication and smaller IBCs with eventual reso-
lution of infection.
Although the IBC cycle is self-limited, invasion of urothelial cells
can result in recurrence through the creation of quiescent intra-
cellular reservoirs. Uropathogenic E. coli (UPEC) have been shown
to remain in the urothelium inside LAMP-1 positive vesicles
(Fig. 1).36 In contrast to IBCs, these quiescent bacteria are non-
replicating and do not elicit an immune response.33 As the
epithelium turns over, these quiescent bacteria are released and
emerge to create new acute infections. These recurrences may
occur for months after the initial acute infection. In this fashion, as
shown in animal models, some species of E. coli possess the abilityto create a state of quiescent infection in the bladder that may be
responsible for multiple recurrences.36
So far, the model for UPEC persistence in the urinary bladder has
not been conﬁrmed in humans. Nevertheless, the presence of IBC
exfoliates and ﬁlamentous bacteria in the urine of women with
RUTI compared to controls suggests that IBC formation with pro-
gression to QIRmay be a reality in humans.30 Evidence supports the
validity of murine model IBC formation as an accurate represen-
tation of human IBC formation. In 2007, Rosen et al30 found human
and murine urine cytologies to be identical. Moreover, E. coli have
been found to have the ability to invade and colonize human
urothelium.37
As in animal models, human urothelium typically undergoes
apoptosis-induced exfoliation upon infection.31 This exfoliation
may be observed by cystoscopy as particulates ﬂoating in the
bladder lumen. Additionally, IBCs may be detectable in human
urine samples. Urine samples have long been considered the
established norm for UTI diagnosis. However, urine cultures that
are found to be culture-negative can contain various bacterial
communities and factors that may not be detectable through the
standard cultivation techniques used for routine urine cultures.38
One such example is bacterial ﬁlaments in the urine. Observation
of bacterial ﬁlaments in the urine through light microscopy and
immunoﬂuorescence is thought to either represent bacteria that
have recently emerged from IBCs or is a result of induction of the
SOS response.39 The presence of these ﬁlaments has been associ-
ated with increased longevity of RUTI symptoms.30 In Rossen
et al’s30 2007 study at the University of Washington involving 100
women aged 18e41 years, 100% of the women with IBCs had ﬁla-
mentous bacteria in their urine compared to only 29% for controls.
At present, the standard for detecting the presence of IBC ﬁlaments
is screening by light microscopy and conﬁrmation via
Table 1
Recurrent urinary tract infection strain analysis.a
Authors (y)ref No. with reinfection/total
no. of women analyzed
Technique % Reinfection by primary infecting
Escherichia coli strain (recurrence)
Jacobson et al (1992)40 19/19 PhP-EC system (BioSys Inova) 47%
Russo et al (1995)41 23/23 Chromosomal restriction
fragment length polymorphism
68%
Ejrnaes et al (2006)42 60/156 Pulsed-ﬁeld gel electrophoresis 77%
Vosti (2007)43 148/203 O serotype grouping by antisera 80.6%, 62.1%, and 68.8% for each
of the ﬁrst 3 mo, respectively
Skjøt-Rasmussen et al (2011)44 10/13 Pulsed-ﬁeld gel electrophoresis 77%
Beerepoot et al (2012)45 35/50 Pulsed-ﬁeld gel electrophoresis 70%
a Using a PubMed search, six studies were found in which the reinfecting strain of E. coli was compared with the primary infecting strain. The aggregate results are
conclusive for neither ascending reinfection (0% reinfection by primary strain) nor quiescent intracellular reservoirs (QIR) recurrence (100% reinfection by primary strain).
There is slight bias towards QIR recurrence with ﬁve of the six studies showing a reinfection rate by primary strain > 50%. Overall, the results suggest that both ascending
reinfections as well as QIR recurrence are likely causes of recurrent urinary tract infection in women.
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urine sample impractical due to both time and ﬁnancial limitations.
Current evidence supports both ascending reinfection (Fig. 2)
and QIR recurrence as models for RUTI. In six studies of women
experiencing RUTI following a primary infection, the rate reinfec-
tion by primary strain varied from 47% to 81%.40e45 Although ﬁve of
the six studies propose a slightly higher rate of reinfection by QIR
recurrence (> 50% reinfection by primary strain),41e45 the aggre-
gated results suggest that both ascending reinfection and QIR
recurrence are signiﬁcant causes of RUTI in women (Table 1).
4. Risk factors
Risk factors for RUTI are less well deﬁned than for UTI alone, and
can be divided between pre- and postmenopausal groups. In pre-
menopausal women, sexual intercourse and a prior history of UTI
are the factorsmost associatedwith recurrence. Diaphragm use and
exposure to oral contraceptives and spermicides have also been
independently shown to be important risk factors.10 Although it is
accepted that the majority of RUTI occur in women with anatomi-
cally normal urinary tracts, a study involving a total of 213 college
age women indicated a signiﬁcantly shorter analeurethral distance
of < 4.5 cm [95% conﬁdence interval (CI), 1.2e4.8; p ¼ 0.013] in
those suffering from RUTI compared to controls suggesting a role
for variations in pelvic anatomy.46 Many women believe that
certain behavior patterns such as pre- and post-coital voiding,
frequency of urination, delayed voiding habits, wiping patterns,
douching, hot tub usage, choice of clothing, and body mass index
may have an association with risk of RUTI. However, in a single
study involving 229 womenwith a history of RUTI and 253 controls
(no UTI in the preceding 12 months and no period of fewer than 1
UTI in any 12 month period), none of these plausible behavioral
factors were shown to signiﬁcantly increase the risk of RUTI
(p < 0.05).10
Risk factors for RUTI in postmenopausal women have been less
well described. A caseecontrol study by Raz et al47 comparing 149
postmenopausal women with a history of RUTI to 53 age-matched
controls reported that a history of RUTI and nonsecretor status
were strongly associated with RUTI. Likewise, in the same study,
urodynamic factors of incontinence (41% vs. 9% control, p < 0.001),
residual urine volume (28% vs. 2% control, p < 0.001), and presence
of a cystocele (19% vs. 0% control, p < 0.001) were shown to pre-
dispose these women to recurrence.47 Estrogen levels also seem to
play an important role. Reduced levels of estrogen result in an
increased vaginal pH, decreased endogenous vaginal microﬂora,
and increased incidence of prolapse due to muscle weakness.48
Each of these factors may predispose women to pathogenic E. coli
colonization. Furthermore, in murinemodels, decreases in estrogenhave been found to be related to delayed development of the
protective bladder glycosaminoglycan layer, increasing suscepti-
bility to bacterial colonization and IBC formation.49 Post-
menopausal women aged  70 years face unique challenges with
regard to RUTI due to institutionalization and decreased functional
status. Increased rates of catheterization, incontinence, and pro-
lapse surgery lead to a substantial increase in risk of RUTI in this
speciﬁc population.
The fact that the vast majority of RUTI are clustered in healthy
women who have anatomically and functionally normal urinary
tracts suggests the presence of underlying genetic factors related to
decreased bladder defenses. These genetic differences among in-
dividuals may be characterized at a superﬁcial level through family
history. Predisposition to RUTI has been shown to have strong fa-
milial linkage. A caseecontrol study of 1278 women aged 18e49
years found the risk of RUTI and pyelonephritis to be increased for
womenwho had at least one female relative with a reported UTI.50
This genetic increased risk of RUTI was found to be similar in
magnitude to that of four to eight episodes of intercourse/month,
odds ratio (OR) 5.0 (95% CI, 3.1e8.1) versus OR 5.8 (95% CI, 3.1e
10.6), respectively.10,50 Among all female relatives, a history of RUTI
in the mother has been shown to most strongly predispose to RUTI
in the daughter.10 The increased risk of RUTI among relatives may
also be attributed in part to common environmental factors or
behaviors.
More speciﬁcally, polymorphisms between individuals may
include differences in blood groups and cell-mediated immunity.
That bacteria can cross-react with ABO blood groups has been
known since the 1960s. As a result, womenwho are nonsecretors of
blood group antigens B or AB are up to four times more susceptible
to RUTI.51 It is hypothesized that anti-B isohemagglutinins may
interact with speciﬁc blood group like antigen binding sites on the
bacterial cell wall, thereby inhibiting uroepithelial attachment.52
Given that neutrophil-defense is essential for cell-mediated UTI
resistance, cytokine polymorphisms or deﬁciencies may alter
neutrophil recruitment and predispose to RUTI. A 2005 study by
Smithson et al53 of 20 premenopausal women aged 21e36 years
noted that decreased levels of the CXCR2 IL-8 receptor could lead to
RUTI susceptibility in women with a history of childhood UTIs.
Presumably this decrease of CXCR2 leads to poor neutrophil
chemotaxis. Knockout mice for the murine IL-8 receptor homo-
logue show ﬁndings similar to humans with decreased CXCR2
expression: the mice were unable to clear bacterial infections from
their kidney and bladder and developed systemic disease.54 Toll-
like receptors (TLR) are a family of receptors that become acti-
vated upon recognizing pathogen associatedmolecules, resulting in
leukocyte recruitment and host-defense gene transcription. A 2009
caseecontrol study by Hawn et al55 investigated TLR genes in more
Table 2
Sample of uropathogenic Escherichia coli virulence factors.a
Type Name Function Gene
Adhesion62,84 Type 1 ﬁmbriae Adhesion, urothelial binding and invasion, IBC formation ﬁmH
Adhesion62 P ﬁmbriae Adhesion, urothelial binding, associated with pyelonephritis PapG
Iron metabolism63,84,85 Aerobactin
siderophore receptor
Ferric iron uptake iutA
Toxin/nitrogen
metabolism84,86,87
Urease Cleaves urea to NH3 and CO2 Ure
Toxin65 a-hemolysin Erythrocyte lysis, tissue injury, urothelial exfoliation, host signal modulation hlyA
Protection65 Serum survival protein Impairs complement activity at outer membrane iss
Protection65,84,88 K1 capsule Shields bacteria from phagocytosis, blocks alternative complement kpsMT
a Uropathogenic E. coli possess a diverse array of virulence factors, each of which contributes to infection of the urinary tract. No single virulence factor is sufﬁcient for
infection. Rather, it is the cumulative effect of multiple factors (protective, toxigenic, metabolism, adhesion) that allows for infection of the urinary tract.59
Table 3
Recurrent urinary tract infection (RUTI) studies: postmenopausal women versus controls.a









Raz et al (2000)47 149 53 65.7  7.2 66.6  6.6 Incontinence, cystocele, and post voiding residual urine
are strongly associated with RUTI
Raz et al (2003)89 86 (estriol pessary) 85 (nitrofurantoin) 68  7.2 66.9  7.9 Estriol vaginal pessaries are less effective than oral
nitrofurantoin in RUTI prevention
Zhong et al (2011)16 37 (continuous) 31 (intermittent) 62.3  7 62.8  7.3 Single-dose patient-initiated antibiotic prophylaxis
is as effective as low-dose daily antibiotic prophylaxis
for preventing RUTI
a Using a PubMed search, only three studies since 2000were found to include both exclusively postmenopausal women and RUTI. Of these three studies, twowere authored
by Raz et al,47,89 one focusing on risk factors for RUTI and the other on comparative treatment of RUTI by estriol vaginal ring versus oral nitrofurantoin. Most recently, a 2011
study by Zhong et al16 on prophylaxis dosing regimens found single-dose patient-initiated antibiotic prophylaxis to be as effective as low-dose daily antibiotic prophylaxis for
preventing RUTI.
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TLR5 receptor, responsible for recognizing the ﬂagellin of mobile
bacteria, were found to result in increased susceptibility to RUTI but
not pyelonephritis (OR, 1.81; 95% CI, 1.00e3.08). Additionally,
reduced levels of TLR4 were found in women with recurrent
asymptomatic bacteriuria compared with controls.55 TLR4 is
responsible for detecting the lipopolysaccharide from Gram-
negative bacteria.33 The genetic background of susceptibility to
RUTI is not fully understood, but remains an important area of
investigation. Further investigation in this area may help lead to
early identiﬁcation of adults predisposed to RUTI and prediction of
recurrence rates in offspring.4.1. RUTI strains and models
The causative agent in the majority of RUTI is UPEC.33 Unlike
UTIs, studies speciﬁcally genotyping all bacteria that can cause RUTI
are scarce. An older study by Stamey and Sexton21 indicated that
women suffering from RUTI had a higher percentage of coloniza-
tion with E. coli, E. faecalis, Proteus mirabilis, and Klebsiella than did
womenwithout a history of RUTI. Colonizationwith Gram-negative
bacilli was found to be more proliﬁc and longer lasting in women
with RUTI.21 Evidence suggests that these bacterial species, UPEC in
particular, may bemore common RUTI causative agents due to their
greater propensity for making IBCs with subsequent QIR forma-
tion.30 A 2006 RUTI species genotyping study found that 77% of
RUTI are caused by relapse with a UPEC strain identical to the
primary infecting strain.42 Additionally, a 2000 study of college age
women found the risk of a secondary infection within a 6-month
time frame for E. coli to be 23% versus 7% for non-E. coli infections.56
Because of its prevalence and responsiveness to manipulation,
E. coli is ﬁttingly the most common model for RUTI study. Two
strains in particular, CFT073 and UTI89, have been thoroughly
investigated. Neither CFT073 nor UTI89 was isolated from patients
suffering from RUTI. CFT073 was originally isolated from the bloodand urine of a woman with acute pyelonephritis whereas UTI89
was isolated from a patient suffering from acute cystitis.57,58 The
UPEC genome is amosaic continuum such that no single feature can
be used to differentiate strains. Similarly, no virulence factor alone
is sufﬁcient to cause disease.59 However, through observation,
some generalities can be made distinguishing CFT073 from UTI89:
CFT073 has the ability to form IBCs, but is also extremely toxic,
causing severe damage to the urothelium. UTI89 is likewise highly
toxic, but has a higher propensity for intracellular invasionwith IBC
formation and progression to QIRs.60
Common among all UPECs, including CFT073 and UTI89, are
virulence factors of various types that together allow for the
establishment of urinary tract infections. One such group of viru-
lence factors is adhesion molecules, which mediate urothelial
attachment and bladder invasion. Of the adhesions molecules, type
1 ﬁmbriae and P ﬁmbriae have been best characterized.61,62 Type 1
ﬁmbriae are more associated with IBC formation whereas P
ﬁmbriae have a close association with pyelonephritis.8 UPEC also
must overcome the challenge of obtaining iron from their envi-
ronment. Iron is the limiting nutrient for UPEC in the urinary
tract.63 UPEC accomplishes this feat through the use of iron binding
siderophores and siderophore receptors, effectively creating a
siderophoreeiron receptor that is taken up by the bacteria with
iron being released into the cytosol.33,63,64 UPEC creates many
toxins that have the ability to not only mediate cell lysis causing
tissue damage and exfoliation, but also to modulate host-signaling
pathways. One such example of host modulation is the disruption
of phagocyte function.65 Along with IBC formation, UPEC have
intrinsic protective factors that can confer resistance to phagocy-
tosis, opsonization, and lysis (Table 2).654.2. RUTIs in postmenopausal women
It is accepted that older women are more likely to get a UTI and
suffer from recurrence. Overall, approximately 10e15% of women
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prospective study by Ikäheimo et al6 followed 179 adult women for
12 months after a UTI episode caused by E. coli. They found a 55%
recurrence rate in women over 55 years compared to 36% in
younger women. This increased susceptibility with age may be due
in part to a natural decrease in inﬂammatory and immune functions
as well as a decrease in postmenopausal estrogen. Bacteriuria can
also be found in up to 40% of elderly, noninstitutionalizedwomen.66
Despite the fact that recurrence occurs more frequently in the
elderly than in any other age group, the vast majority of RUTI
research has been performed in younger women. As a result, there
is a surprising absence of literature about RUTI in postmenopausal
women. Many RUTI studies include postmenopausal women in
their cohorts, but few studies have focused speciﬁcally on this
population. In reviewing literature since 2000, wewere able to ﬁnd
only three studies directly involving both postmenopausal women
and RUTI. Of these three studies, two involved treatment options
whereas one focused on risk factors. Lacking are studies on the
mechanism behind recurrence in the elderly, what species may be
causing these infections, and treatment options speciﬁc for post-
menopausal women (Table 3).
4.3. Current treatment strategies
Treatments for UTI and RUTI are similar in that the ﬁrst line of
defense involves antibiotic therapy. Trimethoprim/sulfamethoxa-
zole (TMP-SMX), ﬂuoroquinolones (Ciproﬂoxacin), b-lactams, and
nitrofurantoin (Macrobid) are the most common antimicrobial
agents used in daily practice.8 However, dosing regimens may
differ in women with frequent RUTI, favoring patient-initiated
treatment when symptoms start, postcoital therapy, and long-
term daily prophylaxis.66 In a Cochrane meta-analysis, 10 out of
19 trials evaluated explored antibiotic prophylaxis versus placebo.
During prophylaxis, the rates of recurrence were found to be 0e
0.9/person/year compared to 0.8e3.6 in the placebo group. The
relative risk of at least one recurrence was found to be 0.21 (95%
CI, 0.13e0.33) in support of antibiotic prophylaxis.67 The deter-
mining factor in whether antimicrobial prophylaxis should be
tried is typically the degree of discomfort felt upon an infection.20
Empiric evidence suggests a 6-month prophylaxis period may
decrease rate of recurrence.7,68 Nevertheless, there remains no
decisive conclusion on the optimal duration of prophylaxis and in
some cases simple postcoital prophylaxis may be as effective as
long-term therapy.67 Unless behavioral patterns such as sexual
activity or diaphragm and spermicide use are changed, women
tend to relapse back to their previous pattern of recurrent in-
fections once prophylaxis is stopped. An estimated 40e60% of
women suffer from recurrence within 6 months of ending
prophylaxis.69
One advantage of single dose postcoital antibiotics over prophy-
laxis is a lower net dose of antibiotics.70 Many uncontrolled studies
have been published comparing postcoital efﬁcacy for decreasing
rate of reinfection for various antibiotics versus continuous pro-
phylaxis. Each of these studies supports a similar magnitude of
reduction of reinfection with postcoital TMP-SMX, nitrofurantoin,
cephalexin, ﬂuoroquinolones, and ciproﬂoxacin when compared to
prophylaxis.71e76 To our knowledge, only oneplacebo controlled trial
for postcoital prophylaxis has shownadecrease in cystitis recurrence
rate with postcoital TMP-SMX of 40/200 mg (0.3/patienteyear)
compared to placebo (3.6/patienteyear).77
Treatment for RUTI is generally the same for postmenopausal as
for premenopausal women. It is accepted that if complicating fac-
tors can be excluded, antibiotic treatment should be carried out as
for premenopausal women.48 One additional treatment option is
available for postmenopausal women in the form of estrogentherapy. An older double-blind, placebo-controlled study of 93
postmenopausal women by Raz and Stamm78 indicated that
vaginal estriol treatment dramatically decreased rates of recur-
rence (0.5 episodes/year compared with 5.9 for placebo). More
recently, Eriksen79 obtained similar results with an estradiol
vaginal ring with 45% of women receiving estradiol being free of
recurrence versus only 20% for placebo. Studies involving oral es-
trogens have been less conclusive. A Cochrane review analyzed four
studies involving a total of 2798 women treated with oral estrogen
versus placebo. They found no statistically signiﬁcant difference in
rates of recurrence (RR, 1.08, 95% CI, 0.88e1.33).80 Clinically, es-
trogen therapy is currently recommended for patients that are
either infected with antibiotic-resistant uropathogens or in pa-
tients whose recurrence may be related to atrophic vaginitis.48
Treatment of recurrence due to QIRs is difﬁcult. Due to the rapid
kinetics of IBC formation, there exists only a small window inwhich
to treat prior to when antibiotics are unable to penetrate the bio-
ﬁlm. Once bioﬁlm formation is complete, few treatment options
remain and progression to QIR is likely. One possible method for
dealing with established QIRs involves the physical destruction of
the involved urothelium. The tissue can be destroyed through a
short outpatient endoscopic fulguration of the trigonal areas
involved with chronic infection (trigonitis). Our group has reported
preliminary encouraging data on this approach, with long-term
follow-up still lacking.81
Anecdotal evidence has long supported cranberry juice as a
treatment option for RUTI in women. However, recent studies have
failed to ﬁnd any such protective value. A 2011 study by Barbosa-
Cesnik et al82 of 319 college women was unable to ﬁnd any
decrease in the 6-month incidence of UTI recurrence among those
drinking 225 g of 27% cranberry twice daily compared to placebo.
Likewise, Stapleton et al83 could not ﬁnd any signiﬁcant (p < 0.05)
reduction in risk of RUTI between 120 women aged 18e45 years
taking 225 g of cranberry daily versus 56 women receiving placebo.
Interestingly, cranberry juice was found to reduce the rate of
symptomatic UTI caused by P-ﬁmbriated E. coli strains. Although
not statistically signiﬁcant, this observation lends support to the
hypothesis that cranberry or a breakdown metabolite may inhibit
P-ﬁmbriated E. coli attachment to the bladder epithelium, giving a
plausible biological mechanism explanation for the proposed efﬁ-
cacy of cranberry juice.83 To our knowledge, no studies exploring
the efﬁcacy of cranberry prophylaxis exclusively in postmenopausal
women have been performed.
5. Conclusion
RUTI is a prevalent and challenging condition among women of
all ages. At present, there are two models to explain RUTI: repeated
reinfection from the fecaleperinealeurethral route and IBC pro-
gression leading to QIR recurrence. Among UPEC, both CFT073 and
UTI89 have been extensively studied, including their propensity for
bioﬁlm production. However, it is not known if these strains
represent the dominant forms of E. coli encountered inwomenwith
RUTI. RUTI management remains difﬁcult with treatment largely
based on antibiotic regimens of various durations. RUTI has been
studied more extensively in younger women than in post-
menopausal women. Given the aging of our population, and the
growing issues of antibiotic allergies and bacterial resistance, this
gap in knowledge must be bridged in the future.
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